Leadership Overview
Divi's Laboratories has 4 executives leading key functions including strategy, corporate governance, digital infrastructure, and financial management.
Focused on high-quality pharmaceutical manufacturing, Divi's Laboratories drives global health outcomes through the production of complex generic APIs, advanced intermediates, and specialized nutraceutical ingredients for international markets.
Focused on high-quality pharmaceutical manufacturing, Divi's Laboratories drives global health outcomes through the production of complex generic APIs, advanced intermediates, and specialized nutraceutical ingredients for international markets.
Leadership Roles at Divi's Laboratories
Kiran Divi - Chief Executive Officer
Kiran Divi, the Chief Executive Officer at Divi's Laboratories, directs the overarching strategic vision for pharmaceutical manufacturing operations. Overseeing the production of generic APIs and complex intermediates, the Chief Executive Officer ensures alignment with rigorous international quality standards. This leadership role involves scaling manufacturing capacity to meet rising global demand for nutraceutical ingredients. By optimizing supply chain efficiency, Kiran Divi directly impacts the competitive market position of the organization. The Chief Executive Officer maintains constant communication with the Board to refine long-term growth objectives. Through the implementation of advanced synthesis technologies, Divi enhances operational output across all facilities. This executive leadership fosters a culture of precision and innovation, ensuring the company remains a leader in the pharmaceutical sector. Ultimately, the Chief Executive Officer secures the future stability of the enterprise by prioritizing sustainable manufacturing practices and expanding the reach of the product portfolio into diverse global markets.
Kishorebabu Lingamneni - Chief Financial Officer
Kishorebabu Lingamneni, the Chief Financial Officer at Divi's Laboratories, directs the financial strategy and capital allocation for the pharmaceutical manufacturing enterprise. Overseeing the management of fiscal resources, the Chief Financial Officer ensures the company maintains a strong balance sheet to support ongoing research and infrastructure investments. This leadership role involves monitoring global market trends to mitigate financial risks associated with raw material procurement and international trade. By optimizing cost structures, Kishorebabu Lingamneni directly impacts the profitability of the generic API and nutraceutical divisions. The Chief Financial Officer coordinates with the Board to provide transparent financial reporting and strategic guidance on capital expenditure. Through the rigorous analysis of operational performance metrics, Lingamneni supports the executive team in making data-driven decisions. This executive leadership fosters financial discipline and long-term value creation for stakeholders. Ultimately, the Chief Financial Officer secures the fiscal health of the organization by maintaining robust liquidity and supporting sustainable growth initiatives.
Manoranjan Jasti - Chief Information Officer
Manoranjan Jasti, the Chief Information Officer at Divi's Laboratories, directs the digital transformation and technological infrastructure supporting pharmaceutical manufacturing. Overseeing the integration of data analytics into production workflows, the Chief Information Officer ensures real-time visibility across all manufacturing sites. This leadership role involves securing proprietary synthesis data and protecting intellectual property through advanced cybersecurity protocols. By implementing scalable cloud solutions, Manoranjan Jasti optimizes the efficiency of internal communication and operational reporting. The Chief Information Officer collaborates with the executive team to leverage technology for improved supply chain transparency and regulatory compliance. Through the deployment of automated systems, Jasti enhances the precision of chemical manufacturing processes. This executive leadership drives the adoption of digital tools to maintain a competitive edge in the global pharmaceutical industry. Ultimately, the Chief Information Officer secures the technological foundation of the company, ensuring robust data management and operational continuity across all regional business units.
Murali Divi - Managing Director
Murali Divi, the Managing Director at Divi's Laboratories, architects the corporate governance framework and long-term institutional development. Overseeing the expansion of research and development capabilities, the Managing Director ensures the company maintains a robust pipeline of custom synthesized APIs. This leadership role involves navigating complex regulatory landscapes to facilitate international market penetration. By fostering strategic partnerships with global pharmaceutical entities, Murali Divi strengthens the market influence of the organization. The Managing Director coordinates with executive leadership to align operational goals with the core mission of delivering high-quality chemical solutions. Through the oversight of large-scale infrastructure projects, Divi drives the modernization of manufacturing facilities. This executive leadership emphasizes technical excellence and scientific integrity as the foundation for all business activities. Ultimately, the Managing Director secures the long-term viability of the firm by championing continuous improvement and maintaining a focus on high-value pharmaceutical manufacturing processes.
Explore Leadership Teams in Manufacturing
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership LP
RV
SA
MT
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.
Company Leadership GA
MM
VK
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
OrchidPharma Ltd is a vertically integrated pharmaceutical company with established research, manufacturing, and marketing capabilities across multiple therapeutic domains in healthcare. The company aims to build a sustainable organizational ecosystem that motivates individuals to achieve new heights and discover growth avenues. OrchidPharma is driven by values such as innovation and corporate social responsibility, alongside its strategic goals. Its intended clients include healthcare providers and organizations seeking comprehensive pharmaceutical solutions.
Company Leadership KP
NA
PP
MS
Frequently Asked Questions Regarding Divi's Laboratories Top Executives and Leadership Team
